Your starting point for classification, predicates, pathways, guidances, standards and controls. Sherpa turns a plain-language device description into an underpinned regulatory strategy.
FDA Reviewer
FDA Reviewer helps you find gaps and inconsistencies in regulatory submissions before regulators do, reducing the risk of delays, questions and rework.
FDA Researcher
FDA Researcher delivers deep, evidence-backed regulatory answers without the need to manually search and cross-reference dozens of documents.
Dialog window
Guideways.ai has officially launched, bringing AI-driven support to one of the most complex bottlenecks in MedTech: regulatory approval. By automating compliance workflows and guiding teams through FDA and MDR pathways, the platform helps reduce time to market for new technologies.
Get started now with early launch pricing, available until the end of April.
What does building ambitious health technology look like when regulatory approval is part of the equation from day one?
On February 12th, during the Guideways Launch Event in Utrecht, we gathered a group of innovators who are moving the needle in some of the most demanding areas of healthcare: from neonatal intensive care to surgical oncology.
Despite their different domains, they share a singular reality: Regulatory clarity shapes momentum. Below, we have compiled the full “Explorers” interview series. These dialogues dive deep into the complexities of FDA and MDR pathways and how the right strategy and the right AI tools can turn a regulatory hurdle into a competitive advantage.
Building Meaningful Healthcare Innovation
Whether it’s neurotech or orthopedics, the underlying struggle is consistent. Medtech approval and compliance processes are highly complex. Regulatory expertise is scarce and expensive. The required work is incredibly time-consuming and remains error-prone. Guideways was built to change that by providing deeply specialized AI agents that compress weeks of regulatory work into minutes.
1. Axite: Brain Monitoring Beyond the Clinic
Founder: Charlotte Franenberg, Co-founder & CEO Focus: Clinical-grade EEG analysis for home use.
When you blur the lines between clinical diagnostics and personal health, where do you fit in the FDA maze? Charlotte discusses the challenge of implementing controls for a solution that tracks cognitive states like brain fog and seizures over long timespans.
Key Takeaway: Foresight in classification is the difference between a smooth launch and a costly pivot.
2. Neolook Solutions: Precision in the NICU
Founder: Marco D’Agata, Founder & CEO Focus: Video and sound-augmented monitoring for neonatal care.
Operating in the USA requires a shift from European or Singaporean strategies. Marco explains how interpreting FDA guidance and identifying submission gaps early is critical when “trust is everything.”
Key Takeaway: Preparation speaks louder than claims when entering the U.S. market.
3. SPCTR: Clarity in the Operating Room
Founder: Wido Heeman, Co-founder & CEO Focus: Real-time tumor margin detection in oncology surgery.
With an ongoing clinical study, SPCTR must keep their clinical program and regulatory strategy in perfect sync. Wido discusses how AI models in the OR require a specific level of evidence that the FDA demands.
Key Takeaway: Compressing weeks of regulatory search into minutes keeps R&D and Marketing aligned.
4. Clear.bio: The Digital Therapeutic Frontier
Leader: Menno van der Eijk, Head of USA Focus: Digital therapeutics for Type 2 Diabetes remission.
Is it wellness, clinical decision support, or a therapeutic? Menno explores the ambiguity of scaling a personalized nutrition and lifestyle platform into the American regulatory landscape.
Key Takeaway: Scaling into the USA requires a clear distinction between “lifestyle” and “clinical intervention” to unlock reimbursement.
Founder: Dennis Alexander Krap, Co-founder & CEO Focus: Detecting orthopedic implant loosening.
For AtMoves, distilling regulatory requirements into the product design is a prerequisite for clinical partnerships. Dennis shares how valuable it is to be able to identify applicable standards in minutes with Guideways.
Key Takeaway: Expert-level reasoning must be available at the design phase, not just the submission phase.
From Complexity to Clarity: Join the Guideways Explorers
The founders featured above are among the first to join Guideways Explorers, our early access community.
At Guideways, we provide the specialized AI agents needed to optimize your positioning from early concept, saving months on time-to-market and avoiding the “rework trap.”